PURESPRING THERAPEUTICS LIMITED

12543677
Active London

Research and experimental development on biotechnology

46 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
P

PURESPRING THERAPEUTICS LIMITED

12543677

Research and experimental development on biotechnology

Founded 1 Apr 2020 Active London, England 46 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

SYNCONA COLLABORATION (S) LIMITED 1 Apr 2020 — 8 Sept 2020
Accounts Submitted 15 May 2026 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 17 Apr 2026 Next due 14 Apr 2027 9 months remaining
Net assets £30M £13M 2024 year on year
Total assets £34M £16M 2024 year on year
Total Liabilities £4M £2M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

8 Bloomsbury Street London WC1B 3SR England

Telephone

0800 000 0000

Website

www.example.com

Full company profile for PURESPRING THERAPEUTICS LIMITED (12543677), an active life sciences and medical technology company based in London, England. Incorporated 1 Apr 2020. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 2 months remaining

Net Assets, Total Assets & Total Liabilities (2020–2024)

Cash in Bank

£28.02M

Increased by £13.31M (+90%)

Net Assets

£29.78M

Increased by £13.45M (+82%)

Total Liabilities

£4.22M

Increased by £2.43M (+136%)

Turnover

N/A

Employees

46

Increased by 16 (+53%)

Debt Ratio

12%

Increased by 2 (+20%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2022
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (5)

Investor NameInvestor SinceParticipating Rounds
Investor 4Nov 2020Series B, Series A
Investor 1Oct 2024Series B
Investor 2Oct 2024Series B

Share Capital

Share Capital

Share allotments and capital structure

12 Allotments 149,339,352 Shares £98.83m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
5 Sept 202510,558,902£63k£0.006
4 Sept 202523,333,334£17.50m£0.75
8 Oct 202447,472,341£35.60m£0.75
8 Oct 202424,843,892£10.56m£0.425
10 Jul 20245,357£294.635£0.055

Officers

Officers

2 active 1 resigned
Status
Ahmad, HaseebDirectorBritishUnited Kingdom5020 May 2025Active
Tsai, John, DrDirectorAmericanSwitzerland5828 Jun 2023Active

Shareholders

Shareholders (136)

Syncona Portfolio Limited
23.1%
35,100,000
Syncona Portfolio Limited
16.4%
24,843,892

Persons with Significant Control

Persons with Significant Control (2)

2 Active

Syncona Limited

British Channel Islands

Active
Notified 1 Apr 2020
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Syncona Limited

Unknown

Active
Notified 1 Apr 2020
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent

Group Structure

Group Structure

PURESPRING THERAPEUTICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
21 May 2026CapitalCapital Variation Of Rights Attached To Shares
21 May 2026CapitalCapital Name Of Class Of Shares
21 May 2026CapitalCapital Name Of Class Of Shares
21 May 2026CapitalCapital Variation Of Rights Attached To Shares
15 May 2026AccountsAnnual accounts made up to 31 Dec 2025
21 May 2026 Capital

Capital Variation Of Rights Attached To Shares

21 May 2026 Capital

Capital Name Of Class Of Shares

21 May 2026 Capital

Capital Name Of Class Of Shares

21 May 2026 Capital

Capital Variation Of Rights Attached To Shares

15 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

Recent Activity

Latest Activity

Capital Variation Of Rights Attached To Shares

1 months ago on 21 May 2026

Capital Name Of Class Of Shares

1 months ago on 21 May 2026

Capital Name Of Class Of Shares

1 months ago on 21 May 2026

Capital Variation Of Rights Attached To Shares

1 months ago on 21 May 2026

Annual accounts made up to 31 Dec 2025

1 months ago on 15 May 2026